TELA Bio Files 8-K on Operations and Reg FD

TL;DR

TELA Bio dropped an 8-K update on financials and Reg FD - check for details.

AI Summary

TELA Bio, Inc. filed an 8-K on October 22, 2024, to report on its results of operations and financial condition, as well as a Regulation FD disclosure. The filing does not contain specific financial figures or details about the nature of the disclosure.

Why It Matters

This filing indicates TELA Bio is providing an update on its financial performance and potentially material information to the public simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for operational and financial condition updates, without immediate indication of significant negative events.

Key Players & Entities

• TELA Bio, Inc. (company) — Registrant
• October 22, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 1 Great Valley Parkway, Suite 24 (address) — Principal executive offices
• Malvern, Pennsylvania (location) — City and State of principal executive offices
• 19355 (zip_code) — Zip code of principal executive offices
• 484-320-2930 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
• $19.0 m — d September 30, 2024 is estimated to be $19.0 million, compared to $15.1 million over t
• $15.1 million — imated to be $19.0 million, compared to $15.1 million over the corresponding period of 2023.
• $17.3 million — he Company ended the third quarter with $17.3 million in cash and cash equivalents, compared
• $46.7 million — cash and cash equivalents, compared to $46.7 million as of December 31, 2023. The above in
• $5.0 million — duce operating expenses in the range of $5.0 million to $10.0 million on an annualized basis
• $10.0 million — xpenses in the range of $5.0 million to $10.0 million on an annualized basis for the fiscal y

Filing Documents

• tm2426600d1_8k.htm (8-K) — 33KB
• 0001104659-24-110552.txt ( ) — 205KB
• tela-20241022.xsd (EX-101.SCH) — 3KB
• tela-20241022_lab.xml (EX-101.LAB) — 33KB
• tela-20241022_pre.xml (EX-101.PRE) — 22KB
• tm2426600d1_8k_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition. The information in Item 7.01 below, except the section titled "Guidance Update," is hereby incorporated by reference into this Item 2.02.

01

Item 7.01 Regulation FD Disclosure. TELA Bio, Inc. (the " Company ") is disclosing certain preliminary financial results for the third quarter ended September 30, 2024. Preliminary Third Quarter Results: Preliminary unaudited operating results for the three months ended September 30, 2024 and certain preliminary financial condition information as of September 30, 2024 are as follows: Revenue for the three months ended September 30, 2024 is estimated to be $19.0 million, compared to $15.1 million over the corresponding period of 2023. Gross margin for the three months ended September 30, 2024 is estimated to be approximately 68%, compared to 69% over the corresponding period of 2023. The Company ended the third quarter with $17.3 million in cash and cash equivalents, compared to $46.7 million as of December 31, 2023. The above information is preliminary financial information as of and for the three months ended September 30, 2024 and is subject to completion. The unaudited, estimated results as of and for the three months ended September 30, 2024 are preliminary and were prepared by the Company's management, based upon the Company's estimates, a number of assumptions and currently available information, and are subject to revision based upon, among other things, quarter-end closing procedures and/or adjustments, the completion of the Company's interim financial statements and other operational procedures. This preliminary financial information is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not completed the Company's financial closing procedures for the three months ended September 30, 2024, and the Company's actual results could be materially different from this preliminary financial information, which preliminary information should not be regarded as a representation by the Company or the Company's management as to the Company's actual results as of and for the

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking on Form 8-K include statements regarding the Company's operating expense reduction and revenue guidance. Such statements are based on information available to the Company as of the date of this Current Report on Form 8-K and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations, and you are cautioned that any such forward-looking statements are not guarantees of future performance. Such risks and uncertainties are described in the Company's periodic reports, including its annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this Form 8-K speak only as of the date of this Form 8-K, and the Company assumes no obligation to updates to these forward-looking statements whether as a result of new information, future events or otherwise after the date of this Current Report on Form 8-K, except as required under applicable law.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: October 22, 2024

View Full Filing

View this 8-K filing on SEC EDGAR